Generic Feraheme Availability

Feraheme is a brand name of ferumoxytol, approved by the FDA in the following formulation(s):

FERAHEME (ferumoxytol - solution;intravenous)

  • Manufacturer: AMAG PHARMS INC
    Approval date: June 30, 2009
    Strength(s): EQ 510MG IRON/17ML (EQ 30MG IRON/ML) [RLD]

Has a generic version of Feraheme been approved?

No. There is currently no therapeutically equivalent version of Feraheme available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Feraheme. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives
    Patent 6,599,498
    Issued: July 29, 2003
    Inventor(s): Ernest V.; Groman & Kenneth G.; Paul & Timothy B.; Frigo & Howard; Bengele & Jerome M.; Lewis
    Assignee(s): Advanced Magnetics, Inc.
    Compositions, methods of making the compositions, and methods of using the compositions are provided for an enhanced magnetic resonance imaging agent and a hematinic agent, the agents comprising carboxyalkylated reduced polysaccharides coated ultrasmall superparamagnetic iron oxides. Methods of use of the carboxymethyl reduced dextran as a plasma extender are provided.
    Patent expiration dates:
    • June 30, 2023
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof
    Patent 7,553,479
    Issued: June 30, 2009
    Inventor(s): Groman; Ernest V. & Paul; Kenneth G. & Frigo; Timothy B. & Bengele; Howard & Lewis; Jerome M.
    Assignee(s): AMAG Pharmaceuticals, Inc.
    Compositions, methods of making the compositions, and methods of using the compositions are provided for an enhanced magnetic resonance imaging agent and a hematinic agent, the agents comprising carboxyalkylated reduced polysaccharides coated ultrasmall superparamagnetic iron oxides. Methods of use of the carboxymethyl reduced dextran as a plasma extender are provided.
    Patent expiration dates:
    • March 8, 2020
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
    Patent 7,871,597
    Issued: January 18, 2011
    Inventor(s): Groman; Ernest V. & Paul; Kenneth G. & Frigo; Timothy B. & Bengele; Howard & Lewis; Jerome M.
    Assignee(s): AMAG Pharmaceuticals, Inc.
    Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL/sec to less than 1 mL/min and wherein upon administration the complex provides minimal detectable free iron in a subject, and minimal incidence of anaphylaxis. The pharmacological compositions are of the type employing a polyol or polyether iron oxide complex, which, upon parenteral administration to a subject, are substantially immunosilent, provide minimal anaphylaxis and minimal free iron, and undergo minimal dissolution in vivo.
    Patent expiration dates:
    • March 8, 2020
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
    Patent 8,501,158
    Issued: August 6, 2013
    Assignee(s): AMAG Pharmaceuticals, Inc.
    Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL/sec to less than 1 mL/min and wherein upon administration the complex provides minimal detectable free iron in a subject, and minimal incidence of anaphylaxis. The pharmacological compositions are of the type employing a polyol or polyether iron oxide complex, which, upon parenteral administration to a subject, are substantially immunosilent, provide minimal anaphylaxis and minimal free iron, and undergo minimal dissolution in vivo.
    Patent expiration dates:
    • March 8, 2020
      ✓ 
      Patent use: METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT
  • Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
    Patent 8,591,864
    Issued: November 26, 2013
    Assignee(s): AMAG Pharmaceuticals, Inc.
    Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods.
    Patent expiration dates:
    • March 8, 2020
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web3)